A 12 Week Phase Ib Randomized Investigator and Subject Blinded Placebo Controlled Repeat-dose Study of LLF580

Trial Profile

A 12 Week Phase Ib Randomized Investigator and Subject Blinded Placebo Controlled Repeat-dose Study of LLF580

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs LLF 580 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2018 Planned number of patients changed from 71 to 66.
    • 06 Jun 2018 Planned End Date changed from 11 Jan 2019 to 27 May 2019.
    • 06 Jun 2018 Planned primary completion date changed from 21 Nov 2018 to 4 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top